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Fecundity generally refers to the ability to reproduce.
In biology and demography, fecundity is the potential
reproductive capacity of an organism or population mea-
sured by the number of eggs or seeds. Fecundity under
both genetic and environmental control is the major mea-
sure of fitness, is well studied in population ecology and
can increase or decrease according to current conditions
and certain regulating factors. In times of hardship for a
population such as a dearth of food, the young or juve-
niles and eventually adult fecundity will decrease. eCAM
fecundity refers to the ability of a scientific idea to open
new lines of research or theoretical inquiry. If one quickly
imagines, do any of these criteria really fit the current
status of eCAM? I think so and will wet your appetite
by giving some examples. First let us deal with eCAM
and this analogy. Second we should identify a few eCAM
contributions that are clearly in line with modern
approaches to genomics and its overlays with eCAM.
eCAM fecundity concerns its continued growth. We
have just received the encouraging news from Sophie
Gilmour, Editorial Assistant, Oxford University Press.
Here are the figures from her Executive Summary Q1
2009. There were 195 new manuscripts submitted from
January to March 2009, compared to 71 during the
same period in 2008. this represents a 175% increase.
Because eCAM is evidence based, is it more poised to
become a source of fertile analyses using combined
approaches that are on the one hand CAM and on the
other, first rate with respect to gene analyses that under-
lie disease? There lies, eCAM’s beginning and possible
future fecundity. Where are we with respect to under-
standing the genetic basis? It is desirable for eCAM to
continue in this direction with full speed. This should
help in keeping the current level or even expand our cur-
rent growth. Clearly eCAM has kept abreast of emerging
technologies, as several examples will reveal.
A brief definition is appropriate. Integrated genomics
analyses the genomes of organisms. In modern molecular
biology an organism’s genome is its hereditary informa-
tion encoded in DNA. The field includes intensive efforts
to determine the entire DNA sequence of organisms and
to fine-scale genetic mapping efforts. Research of single
genes does not include genomics unless the aim of this
genetic pathway and functional information analysis is at
consensus elucidating its effect on, place in, and response
to the entire genome’s networks. With this in mind,
clearly CAM strategies should be devoted to zeroing in
or pinpointing targets where effects might be operative
and, with measured effects. Understanding the molecular
mechanisms of disease requires an introduction of molec-
ular diagnostics into medical practice (1). Current medi-
cine employs only elements of molecular diagnostics, and
usually on single genes. Medicine in the post-genomic era
will utilize thousands of molecular markers associated
with disease that are provided by high-throughput
sequencing and functional genomic, proteomic and meta-
bolomic studies.
This spectrum of techniques will link clinical medicine
based on molecularly oriented diagnostics, predict and
prevent disease. To this feat, large-scale and genome-
wide biological and medical data are essential and must
be combined with biostatistical analyses and bioinfor-
matic modeling of biological systems. Collecting, catalog-
ing and comparison of data from molecular studies and
subsequent development of conclusions create the funda-
mentals of systems biology (2). This highly complex ana-
lytical process reflects a new scientific paradigm and may
be referred to as integrative genomics. Genomic studies
provide us with methods to quickly analyze genes and
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properly cited.their products en masse (3). Moving from the ancient to
the modern, Ayurveda, the traditional Indian medicine
(TIM) and traditional Chinese medicine (TCM) remain
the most ancient yet living traditions. According to
Patwardhan, et al., (2005) these are the two ‘great tradi-
tions’ backed by sound philosophical, experiential and
experimental evidence (4). Recent advancements in the
analytical and biological sciences, along with innovations
in genomics and proteomics can play an important role
in validation of these ancient therapies. Western scientific
community views traditional medicines cautiously and
emphasizes concerns related to research, development
and quality. There is insistence on providing evidence.
Ventura (2005) relates this new paradigm to multiple
holistic approaches: osteopathy, homeopathy, chiroprac-
tic, acupuncture, herbal and energy medicine and medi-
tation (5). These interventions can modify the expression
of different endorphin genes and those encoding for
crucial transcription factors in cellular homeostasis.
Extremely low frequency magnetic fields can prime the
commitment to a myocardial lineage in mouse embryonic
stem cells, suggesting that magnetic energy may direct
stem cell differentiation into specific cellular phenotypes
without employing gene transfer technologies. Different
ginseng extracts modulate growth and differentiation in
pluripotent cells and exert wound-healing and anti tumor
effects through opposing activities on the vascular system
so that ancient compounds could become targets for new
approaches in cell therapy. Resulting CAM modalities
may significantly affect signaling and transcriptional
levels of cellular homeostasis. Thus functional genomics
and proteomics and knowledge of cell signaling networks
may contribute substantially to developing a molecular
evidence–based CAM and pave the way to novel
approaches in tissue engineering and regeneration.
Molecular cartography is another term offered by
Chiappelli (2005) (6). This refers to the multifaceted
and intricate array of interacting genes and gene products
that characterize functions and specialization of each
individual cell and the context of cell–cell interaction,
tissue and organ function, and system’s biology.
Where have proteomics been innovative? ‘Oketsu’ is
a pathophysiologic concept in Japanese traditional
(Kampo) medicine, primarily denoting blood stasis/
stagnant syndrome. Matsumoto’s team explored plasma
protein biomarkers and/or diagnostic algorithms for
‘Oketsu’ (7). Sixteen rheumatoid arthritis (RA) patients
were treated with keishibukuryogan (KBG), a represen-
tative Kampo medicine for improving ‘Oketsu’. Hierarch-
ical clustering gave three major clusters (I, II, III). Most
(68.4%) of ‘Oketsu’ samples were clustered in one cluster
as the principal component of cluster I. The remaining
‘Oketsu’ profiles constituted a minor component of clus-
ter II and were all derived from patients cured of the
‘Oketsu’ state at 12 weeks. Construction of a decision
tree addressed the possibility of developing a diagnostic
algorithm for ‘Oketsu’. Results suggest that the patho-
physiologic concept of Kampo medicine ‘Oketsu’ has a
physical basis as measured by blood protein profiles.
We may be able to establish objective criteria for diag-
nosing ‘Oketsu’ using a combination of proteomic
and bioinformatics-based classification methods. Natural
products are gaining increased applications in drug
discovery and development so that there are emerging
applications of DNA microarrays in pharmacodynamics,
pharmacogenomics, toxicogenomics and quality control
of herbal drugs and extracts (8).
Bacterial infections involving multi drug-resistant
strains are one of ten leading causes of death and
an important health problem in need of new antibacterial
sources and agents (9). Four snake venoms (Agkistrodon
rhodostoma, Bothrops jararaca, B. atrox and Lachesis
muta) have been tested against 10 Gram-positive and
Gram-negative drug-resistant clinical bacteria strains to
identify them as new sources of potential antibacterial
molecules. Mushrooms, similar to plants, have great
potential for producing useful bioactive metabolites;
they are a prolific resource for drugs (10). Responsible
bioactive compounds belong to several chemical groups
that are often polysaccharides or triterpenes. One species
can possess bioactive compounds that can exert pharma-
cological effects. The best example is G. lucidum that
contains >120 different triterpenes and polysaccharides,
proteins and other bioactive compounds. The spectrum
of detected pharmacological activities of mushrooms is
broad. Dependent on increasing knowledge of chemistry,
biotechnology and molecular biology of mushrooms
as well as an improvement of screening methods (high
throughput screening, genomics and proteomics), a
rapid increase in the application of examples such as
animal products and mushrooms for medicinal purposes
can be expected.
Fecundity of eCAM is reflected in the increased
number of manuscripts submitted recently and evidence
that eCAM is poised to expand its repertoire to pinpoint
targets of disease that could be modulated by CAM inter-
vention using genomics. However in biomedical research
and all other creative activity, no idea or movement is
rarely clean cut and clear and free from intense scrutiny,
even for an area so very pertinent and basic as genomics.
Koenig (2009) points this out in a brief report under the
section Biomedical Research. Genome Scans: Impatient
for the Payoff (11). A debate in the genomics community
about research strategy recently went public in commen-
taries published online by the New England Journal of
Medicine (NEJM). A central disagreement concerns the
likely value of chip-based genome scans to gauge inher-
ited risks of developing common diseases. The discussion
comes at a time when the U.S. National Human
Research Institute (NHGRI) requests that scientists
help direct its course in a new road map. Researchers
contacted by Science agreed that far more work is
130 Editorialrequired before physicians can properly utilize personal
genomic assessments. Maybe eCAM will join the debate?
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